DAAN GENE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.47 CNY | +0.81% |
|
+0.27% | -22.83% |
| Apr. 26 | Daan Gene Gets Nod to Register Detection Kit for Influenza Viruses, COVID-19 | MT |
| Apr. 01 | Daan Gene Co., Ltd. Proposes Final Cash Dividend for 2023 | CI |
| Sales 2022 | 12.05B 1.66B | Sales 2023 | 1.18B 163M | Capitalization | 13.59B 1.87B |
|---|---|---|---|---|---|
| Net income 2022 | 5.41B 747M | Net income 2023 | 105M 14.49M | EV / Sales 2022 | 1.54 x |
| Net cash position 2022 | 3.33B 460M | Net cash position 2023 | 2.03B 281M | EV / Sales 2023 | 9.78 x |
| P/E ratio 2022 |
4.03
x | P/E ratio 2023 |
130
x | Employees | 1,968 |
| Yield 2022 |
11.2% | Yield 2023 |
0.15% | Free-Float | 65.64% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.81% | ||
| 1 week | +0.27% | ||
| Current month | -10.32% | ||
| 1 month | -10.00% | ||
| 3 months | -13.24% | ||
| 6 months | -21.20% | ||
| Current year | -22.83% |
1 week
7.33
7.59
1 month
7.288.36
Current year
6.669.82
1 year
6.6615.60
3 years
6.6624.18
5 years
5.4432.00
10 years
4.6533.31
| Managers | Title | Age | Since |
|---|---|---|---|
Luo Huang
CEO | Chief Executive Officer | 44 | 21-05-31 |
Wei Jie Zhang
DFI | Director of Finance/CFO | 53 | 15-03-25 |
Xi Wen Jiang
BRD | Director/Board Member | 42 | 21-06-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zheng Fu Zhu
BRD | Director/Board Member | 60 | 22-05-26 |
Zhe Qiang Xue
CHM | Chairman | 36 | 22-07-03 |
Li Qiang Huang
BRD | Director/Board Member | 57 | 03-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.37% | 2 M€ | -16.59% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 7.47 | +0.81% | 11,464,860 |
| 24-04-25 | 7.41 | +0.27% | 8,135,412 |
| 24-04-24 | 7.39 | -1.99% | 12,964,490 |
| 24-04-23 | 7.54 | +0.27% | 10,539,060 |
| 24-04-22 | 7.52 | +0.94% | 11,779,980 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Da An Gene Co., Ltd. specializes in the development, manufacture and marketing of molecular diagnosis products for infectious and epidemic diseases. The group offers real-time polymerase chain reaction instruments (QPCR), immunological products, screening systems for cervical cancer, sequencing tools, blood collection tubes and food safety products.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -22.83% | 1.45B | |
| -19.01% | 56.28M |
- Stock Market
- Equities
- 002030 Stock
